The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Vaccine Contract Manufacturing Market (2nd Edition), 2019-2030 [COVID-19 SERIES]

  • Lowest Price Guaranteed From USD 4,499

  • Published
    July 2019

  • Pages
    406

  • View Count
    6367

Example Insights

Vaccine Contract Manufacturing Market Context Vaccine Contract Manufacturing Market Companies Vaccine Contract Manufacturing Market Market Overview
Vaccine Contract Manufacturing Market Partnerships and Collaborations Vaccine Contract Manufacturing Market Expansions Vaccine Contract Manufacturing Market Competitiveness Analysis
Vaccine Contract Manufacturing Market Demand and Supply Analysis Vaccine Contract Manufacturing Market Market Attractiveness Analysis Vaccine Contract Manufacturing Market Forecast

 

Overview

[COVID-19 SERIES] The global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. According to the WHO, the global vaccination rate is nearly 85%, demonstrating the high clinical demand for vaccines.  In addition to meeting the growing demand for vaccines, the developers of these pharmacological interventions are also plagued by high costs of development and complex production protocols. Given that vaccine manufacturing requires highly regulated, state-of-the-art technologies, it has become increasingly difficult for stakeholders to establish in-house expertise for large-scale manufacturing of vaccines. As a result, vaccine developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs). Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical development and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs.

It is worth highlighting that the contemporary contract services market for vaccines is highly fragmented. Having said that, numerous stakeholders are actively striving to expand their respective service portfolios through substantial acquisition activity. As a result, these CMOs have developed the capabilities to offer end-to-end services, ranging from vaccine development (including preliminary R&D, preclinical studies and clinical trials), to regulatory filings, and commercial scale production. In future, we expect the demand for core competencies to continue to drive sponsor companies to rely on contract service providers for various aspects of product development and manufacturing. Amidst tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry. 

Scope of the Report

The “Vaccine Contract Manufacturing Market (2nd Edition), 2019 – 2030” report features an extensive study on contract service providers engaged in the development and manufacturing of vaccines. The study features in-depth analyses, highlighting the capabilities of various vaccine CMOs. Amongst other elements, the report includes:

  • A detailed review of the contract manufacturing landscape for vaccines, featuring a comprehensive list of active CMOs and analysis based on a number of parameters, such as year of establishment, company size, geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), type of expression systems used (mammalian, microbial and others) and type(s) of vaccines manufactured. 
  • A region-wise, company competitiveness analysis, highlighting prominent vaccine contract manufacturers based on supplier strength (considering the experience of the contract manufacturer), and service strength (which takes into account the count of service offerings, number of expression systems used and scale of operation).
  • Elaborate profiles of the key players based in North America, Europe and Asia-Pacific that have a diverse range of capabilities for the development, manufacturing and packaging of vaccines. Each profile includes an overview of the company, its financial performance (if available), information on service portfolio, vaccine manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook. 
  • An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of vaccines, based on various parameters, such as year of agreement, type of agreement, scale of operation, types of services mentioned in the deal, types of vaccines manufactured, types of therapeutic area and location of facility where the project is to be executed. 
  • A detailed analysis of the expansions undertaken (since 2013) by various service providers within vaccine contract manufacturing industry, based on a number of parameters, including year of expansion, type of expansion (capacity expansion, capability expansion and new facility), geographical location of facility, scale of operation, types of services involved, expansion details (in terms of new area added to existing facilities, if available) and most active players (in terms of number of instances).
  • An informed estimate of the annual commercial and clinical demand for vaccines (in million litres), which was further segmented on various types, such as types of vaccines, types of indications and geography. A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small-sized, mid-sized, large / very large CMOs) in the market, based on data gathered via secondary and primary research. It also provides the distribution of global vaccine manufacturing capacity by company size (small-sized, mid-sized, large / very large), and geography (North America, Europe and Asia-Pacific) and scale of operation (preclinical / clinical and commercial).
  • A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs) in the market, based on data gathered via secondary and primary research. It also provides the distribution of global vaccine manufacturing capacity by company size (small-sized, mid-sized, large and very large), and geography (North America, Europe and Asia-Pacific) and scale of operation (preclinical / clinical and commercial).
  • A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry. 
  • A discussion on the potential market drivers, such as the growing vaccines pipeline, increasing outsourcing of vaccine operations and opportunities in Asia-Pacific region, which are likely to present in the coming years.

One of the key objectives of the report was to estimate the future size of the market. Based on the parameters, such as growth of the overall vaccine market, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period, 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] types of expression systems (mammalian, microbial and others), [B] size of contract service provider company (small-sized, mid-sized and large / very large), [C] scale of operation (preclinical, clinical and commercial) and [D] key geographical regions (North America (US,), Europe (UK, France, Germany, Italy and Spain), Asia (China, India and Japan) and rest of the world. To account for the uncertainties associated with the manufacturing of vaccines and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. 

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Menzo Havenga, CEO, Batavia Biosciences and Claire Otjes, Marketing Manager, Batavia Biosciences
  • David C Cunningham, Director Corporate Development, Goodwin Biotechnology
  • Ingrid Cromann, Director - Vaccine Development, Statens Serum Institut
  • Kevin Daley, Director Pharmaceuticals, Novasep Synthesis
  • Oliver Schub, Senior Business Development Manager, ProBioGen
  • Sebastian Schuck, Head of Business Development, Wacker Biotech 

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the vaccine contract manufacturing market in the mid to long term. 

Chapter 3 provides a general introduction to vaccines. The chapter also includes an overview of the various expression systems used in the development and manufacturing of vaccines. It also features a brief overview of contract manufacturing and a detailed discussion on the need for outsourcing within the vaccines industry. The chapter includes a list of commonly outsourced vaccine manufacturing services, and concludes with a discussion on the challenges that are currently associated within this market.

Chapter 4 provides a comprehensive overview of the global vaccine contract manufacturing landscape. It includes information related to over 90 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as the year of establishment, company size, geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), type of expression systems used (mammalian, microbial and others) and type(s) of vaccines manufactured. 

Chapter 5 features a comprehensive company competitiveness analysis of vaccine contract manufacturers based in North America, Europe and Asia-Pacific, that we came across during our research. The analysis compares companies within each geography on the basis of supplier strength (considering the experience of contract manufacturer) and service strength (which takes into account the count of service offerings, number of expression systems used, and scale of operation).

Chapter 6 provides detailed profiles of some of the key players that are active in the vaccine contract manufacturing market in North America. Each profile presents a brief overview of the company, financial information (if available), its contract service offerings highlighting the capabilities of vaccine product facilities, recent developments and an informed future outlook. 

Chapter 7 provides detailed profiles of some of the key players that are active in the vaccine contract manufacturing market in Europe. Each profile presents a brief overview of the company, financial information (if available), its contract service offerings highlighting the capabilities of vaccine product facilities, recent developments and an informed future outlook. 

Chapter 8 provides detailed profiles of some of the key players that are active in the vaccine contract manufacturing market in Asia-Pacific. Each profile presents a brief overview of the company, financial information (if available), its contract service offerings highlighting the capabilities of vaccine product facilities, recent developments and an informed future outlook. 

Chapter 9 features an elaborate analysis and discussion on the collaborations and partnerships that have been inked amongst players, since 2013. It includes brief descriptions of the various partnership models (including acquisition, distribution agreement, licensing agreements, manufacturing, product development / commercialization, product development and manufacturing, process development and manufacturing, process development, R&D agreements, service alliance and others) that have been adopted by stakeholders in this domain. It also includes analysis based on year of agreement, type of agreement, scale of operation, types of services mentioned in the deal, types of vaccines manufactured, types of therapeutic area and location of facility where the project is to be executed. Further, the chapter features a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 10 presents detailed analysis on the expansions that have taken place in the vaccine manufacturing industry, since 2013. It includes information on expansions for increasing existing capabilities, as well as setting-up of new facilities by service provider entities engaged in this domain. The expansion instances that we came across were analyzed based on various parameters, including year of expansion, type of expansion (capacity expansion, capability expansion and new facility), geographical location of the facility, scale of operation (as mentioned in the expansion terms), types of services involved, expansion details (in terms of new area added to the existing facilities, if available) and also highlights the most active players (in terms of number of instances) in the domain.

Chapter 11 features an analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of vaccine products. The analysis takes into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large / very large CMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global vaccine manufacturing capacity by size of the company (small-sized, mid-sized, large /very large), region of operation (North America Europe, Asia-Pacific and, rest of the world) and scale of operation (preclinical / clinical, commercial).

Chapter 12 features an informed view on the demand for vaccines (both clinical and commercially available) in the market, offering an informed opinion on the required scale of supply (in terms of vaccine manufacturing services). For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of vaccines that have been registered since 2010. The data was analyzed on the basis of various parameters, such as types of vaccines, types of indications and geography. Further, in order to estimate the commercial demand, we considered the annual volume of vaccine doses sold, based on various parameter, such as types of vaccines and geography.
 
Chapter 13 presents an insightful market forecast analysis, highlighting the likely growth of the vaccine contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [[A] types of expression systems (mammalian, microbial and others) [B] size of the company (small-sized, mid-sized and large / very large), [C] scale of operation (preclinical, clinical and commercial) and [D] key geographical regions (North America (US,), Europe (UK, France, Germany, Italy and Spain), Asia (China, India and Japan) and rest of the world.

Chapter 14 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of biopharmaceuticals manufacturing market, under a comprehensive SWOT framework.

Chapter 15 highlights the potential growth drivers for contract vaccine manufacturers. It highlights the various opportunities associated with the growing vaccine pipeline, increase in outsourcing of vaccine manufacturing operations, adoption of innovative technologies and opportunities in Asia-Pacific region, which are likely to have a notable influence on the future of the vaccine contract manufacturing market. 

Chapter 16 features the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the vaccine contract manufacturing domain. We spoke to Menzo Havenga (CEO, Batavia Biosciences) and Claire Otjes (Marketing Manager, Batavia Biosciences), David C Cunningham (Director Corporate Development, Goodwin Biotechnology), Ingrid Cromann (Director - Vaccine Development, Statens Serum Institut), Kevin Daley (Director Pharmaceuticals, Novasep Synthesis), Oliver Schub (Senior Business Development Manager, ProBioGen) and Sebastian Schuck (Head of Business Development, Wacker Biotech).

Chapter 17 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 18 is an appendix that provides the list of companies and organizations mentioned in the report.

 

Table of Contents

1.PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Classification of Vaccines based on the Type of Active Ingredient
3.2.1. Live, Attenuated Vaccines
3.2.2. Inactivated Vaccines
3.2.3. Subunit Vaccines
3.2.4. Toxoid Vaccines
3.2.5. DNA Vaccines

3.3. Key Components within Vaccine Formulations
3.4. Vaccine Development and Manufacturing
3.4.1. Identification of Antigen and Manufacturing Process Development
3.4.2. Production of Vaccines in Different Expression System
3.4.2.1. Bacterial Expression System
3.4.2.2. Yeast Expression System
3.4.2.3. Insect Expression
3.4.2.4. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
3.4.2.5. Plant Expression Systems
3.4.2.6. Avian Expression Systems
3.4.2.7. Mammalian Expression Systems

3.4.3. Vaccine Manufacturing Process
3.4.3.1. Upstream Process
3.4.3.2. Downstream Process
3.4.3.3. Formulation and Fill / Finish
3.4.4. Clinical Development and Approval
3.4.5. Vaccine Supply Chain and Logistics
3.5. Vaccine Contract Manufacturing
3.5.1. Need for Outsourcing Vaccine Manufacturing Operations
3.5.2. Commonly Outsourced Operations
3.5.3. Selecting a CMO Partner
3.5.4. Advantages of Outsourcing Manufacturing Operations
3.5.5. Risk Factors and Challenges

4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Vaccine Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Size of Employee Base
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Manufacturing Facilities
4.2.5. Analysis by Type of Services Offered
4.2.6. Analysis by Scale of Operation
4.2.7. Analysis by Expression System Used
4.2.8. Analysis by Type of Vaccines Manufactured

5.  COMPANY COMPETITIVE ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions and Key Input Parameters

5.4. Competitiveness Analysis: Vaccine Contract Manufacturers in North America
5.4.1. Companies Offering Contract Vaccine Manufacturing Services based on Mammalian Expression System
5.4.2. Companies Offering Contract Vaccine Manufacturing Services based on Microbial Expression System
5.4.3. Companies Offering Contract Vaccine Manufacturing Services based on Other Expression System

5.5. Competitiveness Analysis: Vaccine Contract Manufacturers in Europe
5.5.1. Companies Offering Contract Vaccine Manufacturing Services based on Mammalian Expression System
5.5.2. Companies Offering Contract Vaccine Manufacturing Services based on Microbial Expression System
5.5.3. Companies Offering Contract Vaccine Manufacturing Services based on Other Expression System

5.6. Competitiveness Analysis: Vaccine Contract Manufacturers in Asia-Pacific and Rest of the World
5.6.1. Companies Offering Contract Vaccine Manufacturing Services based on Mammalian Expression System
5.6.2. Companies Offering Contract Vaccine Manufacturing Services based on Microbial Expression System
5.6.3. Companies Offering Contract Vaccine Manufacturing Services based on Other Expression System

6. VACCINE CONTRACT MANUFACTURING IN NORTH AMERICA
6.1. Chapter Overview
6.2. Albany Molecular Research (AMRI) / OSO BioPharmaceuticals Manufacturing (OsoBio)
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Vaccine Manufacturing Services Portfolio
6.2.3.1. Fill / Finish Services
6.2.3.2. Regulatory Support and Quality Assurance Services
6.2.4. Vaccine Manufacturing Facilities
6.2.6. Recent Developments
6.2.6.1. Partnerships
6.2.6.2. Expansions
6.2.6.3. Awards and Accolades
6.2.7. Future Outlook

6.3. Catalent Biologics
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Vaccine Manufacturing Services Portfolio
6.3.3.1. Cell Line Development Services
6.3.3.2. Clinical Manufacturing Services
6.3.3.3. Analytical Services
6.3.3.4. Clinical Supply Services
6.3.3.5. Regulatory Support Services
6.3.4. Vaccine Manufacturing Facilities
6.3.5. Recent Developments
6.3.5.1. Partnerships
6.3.5.2. Expansions
6.3.5.3. Awards and Accolades
6.3.6. Future Outlook

6.4. Charles River Laboratories
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Vaccine Manufacturing Services Portfolio
6.4.3.1. Vaccine Development Services
6.4.3.2. Vaccine Manufacturing Services
6.4.3.3. Avian Vaccine Services
6.4.4. Vaccine Manufacturing Facilities
6.4.5. Recent Developments
6.4.5.1. Partnerships
6.4.5.2. Expansions
6.4.6. Future Outlook

6.5. Meridian Life Science (MLS)
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Vaccine Manufacturing Services Portfolio
6.5.3.1. Cell and Virus Banking Services
6.5.3.2. Process development and Scale-up Services
6.5.3.3. Formulation Development and Fill / finish Services
6.5.3.4. Regulatory Support Services
6.5.4. Vaccine Manufacturing Facilities
6.5.5. Recent Developments
6.5.5.1. Partnerships
6.5.5.2. Awards and Accolades
6.5.6. Future Outlook

6.6. BioReliance (A Unit of Merck)
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Vaccine Manufacturing Services Portfolio
6.6.3.1. cGMP Cell and Virus Banking Services
6.6.3.2. Process Development Services
6.6.3.3. Biorepository Services
6.6.3.4. Contract Manufacturing Support Services
6.6.4. Vaccine Manufacturing Facilities
6.6.5. Recent Developments
6.6.5.1. Partnerships
6.6.5.2. Expansions
6.6.5.3. Awards and Accolades
6.6.6. Future Outlook

7. VACCINE CONTRACT MANUFACTURING IN EUROPE
7.1. Chapter Overview
7.2. Cobra Biologics
7.2.1. Company Overview
7.2.2. Vaccine Manufacturing Services Portfolio
7.2.2.1. Viral Vaccines and Virus based Services
7.2.2.2. DNA Vaccines and DNA based Services
7.2.2.3. Other Services
7.2.3. Vaccine Manufacturing Facilities
7.2.4. Recent Developments
7.2.4.1. Partnerships
7.2.4.2. Expansions
7.2.5. Future Outlook
 
7.3. Eurogentec
7.3.1. Company Overview
7.3.2. Vaccine Manufacturing Services Portfolio
7.3.2.1. Manufacturing Services
7.3.2.2. Analytical and Regulatory Support Services
7.3.2.3. Other Services
7.3.3. Future Outlook

7.4. IDT Biologika
7.4.1. Company Overview
7.4.2. Vaccine Manufacturing Services Portfolio
7.4.2.1. Development Services
7.4.2.2. Vaccine Manufacturing Services
7.4.2.3. Fill / Finish Services
7.4.2.4. Labeling and Packaging Services
7.4.2.5. Storage Services
7.4.2.6. Quality Control Services
7.4.3. Vaccine Manufacturing Facilities
7.4.4. Recent Developments
7.4.4.1. Partnerships
7.4.4.2. Expansions
7.4.4.3. Awards and Accolades
7.4.5. Future Outlook

7.6. Lonza
7.6.1. Company Overview
7.6.2. Financial Information
7.6.3. Vaccine Manufacturing Services Portfolio
7.6.3.1. Process Development and Optimization Services
7.6.3.2. Vaccine Commercial Manufacturing Services
7.6.3.3. Fill / Finish Services
7.6.3.4. Other Services
7.6.4. Recent Developments
7.6.4.1. Partnerships
7.6.4.2. Expansions
7.6.4.3. Awards and Accolades
7.6.5. Future Outlook

8. VACCINE CONTRACT MANUFACTURING IN ASIA PACIFIC AND THE REST OF THE WORLD
8.1. Chapter Overview
8.2. GreenPak Biotech
8.2.1. Company Overview
8.2.2. Vaccine Manufacturing Services Portfolio

8.3. Hong Kong Institute of Biotechnology
8.3.1. Company Overview
8.3.2. Vaccine Manufacturing Services Portfolio
8.3.2.1. Manufacturing Services
8.3.3. Vaccine Manufacturing Facilities

8.4. WuXi AppTec ((WuXi Biologics)
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Vaccine Manufacturing Services Portfolio
8.4.3.1. Non-Clinical Services
8.4.3.2. Discovery and Early Diagnostic Testing Services
8.4.3.3. Support Services
8.4.3.4. Manufacturing Services
8.4.3.5. Vaccine Testing Services
8.4.4. Recent Developments
8.4.4.1. Partnerships
8.4.4.2. Awards and Accolades
8.4.5. Future Outlook

8.5. Bharat Biotech
8.5.1. Company Overview
8.5.2. Vaccine Manufacturing Services Portfolio
8.5.3. Vaccine Manufacturing Facilities
8.5.4. Recent Developments
8.5.4.1. Partnerships
8.5.4.2. Awards and Accolades
8.5.5. Future Outlook

8.6. Biological E
8.6.1. Company Overview
8.6.2. Vaccine Manufacturing Services Portfolio
8.6.3. Vaccine Manufacturing Facilities
8.6.4. Recent Developments
8.6.4.1. Partnerships
8.6.4.2. Expansions
8.6.4.3. Awards and Accolades
8.6.5. Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Vaccine Contract Manufacturing: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Focus Area
9.3.4. Analysis by Scale of Operation
9.3.5. Most Active Players: Analysis by Number of Partnerships
9.3.6. Regional Analysis
9.3.6.1. Intercontinental and Intracontinental Agreements

10. RECENT EXPANSIONS
10.1. Chapter Overview
10.1.1. Vaccine Contract Manufacturing Service Providers: Recent Expansions
10.1.2. Analysis by Year of Expansion
10.1.3. Analysis by Type of Expansion
10.1.4. Analysis by Scale of Operation and Type of Expansion
10.1.5. Analysis by Geographical Distribution
10.1.6. Analysis by Company Headquarters and Company Size
10.1.7. Analysis by Location of Facility and Purpose of Expansion
10.1.8. Analysis by Type of Services Offered
10.1.9. Analysis by Type of Service and Purpose of Expansion
10.1.10. Most Active Players: Analysis by Number of Recent Expansions

11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Vaccine Contract Manufacturing Market: Global Production Capacity (in Liters) 11.3.1.
11.3.2. Analysis by Expression System
11.3.3. Analysis by Scale of Operation
11.3.4. Analysis by Region
11.3.4.1. Production Capacity in North America (in Liters)
11.3.4.2. Production Capacity in Europe (in Liters)
11.3.4.3. Production Capacity in Asia and Middle East (in Liters)
11.4. Conclusion

12. DEMAND ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Global Clinical Demand for Vaccines: Analysis by Number of Trials
12.3.1. Analysis by Trial Registration Year
12.3.2. Analysis by Type of Vaccine
12.3.3. Analysis by Clinical Dose
12.3.4. Analysis by Trial Status
12.3.5. Geographical Analysis by Number of Clinical Trials
12.3.6. Geographical Analysis by Trial Status and Trial Phase
12.3.7. Analysis by Type of Sponsors / Collaborators
12.3.8. Most Active Players

12.4. Global Clinical Demand for Vaccines: Analysis by Enrolled Patient Population
12.4.1. Geographical Analysis by Enrolled Patient Population
12.4.2. Geographical Analysis of Enrolled Patient Population by Trial Phase and Type of Vaccine

12.5. Global Clinical Demand for Vaccines: Annual Demand of Vaccines
12.6. Concluding Remarks
  
13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
 
13.3. Overall Vaccine Contract Manufacturing Market, 2019-2030
13.4. Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Service Portfolio
13.5. Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Expression System Used
13.6. Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation
13.7. Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Size of Manufacturers
 
13.8. Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Geography
13.8.1. Vaccine Contract Manufacturing Market in North America, 2019-2030
13.8.1.1. Vaccine Contract Manufacturing Market in the US, 2019-2030
13.8.1.2. Vaccine Contract Manufacturing Market in Rest of North America, 2019-2030
 
13.8.1.3. Vaccine Contract Manufacturing Market in North America for Mammalian Cell-based Operations, 2019-2030
13.8.1.4. Vaccine Contract Manufacturing Market in North America for Microbial Cell-based Operations, 2019-2030
13.8.1.5. Vaccine Contract Manufacturing Market in North America for Other Expression System-based Operations, 2019-2030
13.8.1.6. Vaccine Contract Manufacturing Market in North America for Preclinical / Clinical Scale Operations, 2019-2030
13.8.1.7. Vaccine Contract Manufacturing Market in North America for Commercial Operations, 2019-2030
13.8.1.8. Vaccine Contract Manufacturing Market in North America for Small-sized Companies, 2019-2030
13.8.1.9. Vaccine Contract Manufacturing Market in North America for Mid-sized Companies, 2019-2030
13.8.1.10. Vaccine Contract Manufacturing Market in North America for Large / Very Large Companies, 2019-2030
 
13.8.2. Vaccine Contract Manufacturing Market in Europe, 2019-2030
13.8.2.1. Vaccine Contract Manufacturing Market in Italy, 2019-2030
13.8.2.2. Vaccine Contract Manufacturing Market in Germany, 2019-2030
13.8.2.3. Vaccine Contract Manufacturing Market in France, 2019-2030
13.8.2.4. Vaccine Contract Manufacturing Market in Spain, 2019-2030
13.8.2.5. Vaccine Contract Manufacturing Market in the UK, 2019-2030
13.8.2.6. Vaccine Contract Manufacturing Market in Rest of Europe, 2019-2030
 
13.8.2.7. Vaccine Contract Manufacturing Market in Europe for Mammalian Cell-based Operations, 2019-2030
13.8.2.8. Vaccine Contract Manufacturing Market in Europe for Microbial Cell-based Operations, 2019-2030
13.8.2.9. Vaccine Contract Manufacturing Market in Europe for Other Expression System-based Operations, 2019-2030
13.8.2.10. Vaccine Contract Manufacturing Market in Europe for Preclinical / Clinical Operations, 2019-2030
13.8.2.11. Vaccine Contract Manufacturing Market in Europe for Commercial Operations, 2019-2030
13.8.2.12. Vaccine Contract Manufacturing Market in Europe for Small-sized Companies, 2019-2030
13.8.2.13. Vaccine Contract Manufacturing Market in Europe for Mid-sized Companies, 2019-2030
13.8.2.14. Vaccine Contract Manufacturing Market in Europe for Large / Very Large Companies, 2019-2030
 
13.8.3. Vaccine Contract Manufacturing Market in Asia and Rest of the World, 2019-2030
13.8.3.1. Vaccine Contract Manufacturing Market in China, 2019-2030
13.8.3.2. Vaccine Contract Manufacturing Market in India, 2019-2030
13.8.3.3. Vaccine Contract Manufacturing Market in South Korea, 2019-2030
13.8.3.4. Vaccine Contract Manufacturing Market in Japan, 2019-2030
13.8.3.5. Vaccine Contract Manufacturing Market in Australia, 2019-2030
13.8.3.6. Vaccine Contract Manufacturing Market in Rest of Asia and Other Regions, 2019-2030
 
13.8.3.7. Vaccine Contract Manufacturing Market in Asia and Rest of the World for Mammalian Cell-based Operations, 2019-2030
13.8.3.8. Vaccine Contract Manufacturing Market in Asia and Rest of the World for Microbial Cell-based Operations, 2019-2030
13.8.3.9. Vaccine Contract Manufacturing Market in Asia and Rest of the World for Other Expression System-based Operations, 2019-2030
 
13.8.3.10. Vaccine Contract Manufacturing Market in Asia and Rest of the World for Preclinical / Clinical Operations, 2019-2030
13.8.3.11. Vaccine Contract Manufacturing Market in Asia and Rest of the World for Commercial Operations, 2019-2030
 
13.8.3.12. Vaccine Contract Manufacturing Market in Asia and Rest of the World for Small-sized Companies, 2019-2030
13.8.3.13. Vaccine Contract Manufacturing Market in Asia and Rest of the World for Mid-sized Companies, 2019-2030
13.8.3.14. Vaccine Contract Manufacturing Market in Asia and Rest of the World for Large / Very Large Companies, 2019-2030

14. SWOT ANALYSIS
14.1 Chapter Overview
14.2. Strengths
14.3. Weaknesses
14.4. Opportunities
14.5. Threats
14.6. Comparison of Swot Factors
14.7. Concluding Remarks

15. FUTURE TRENDS
15.1. Chapter Overview
15.2. Adoption of Innovative Technologies to Drive Growth
15.3. Shift to Single Use Systems and Components
15.4. The Advent of Virus-like Particles (VLPs)
15.5. Growing Investments in Existing Infrastructure
15.6. Evolving Client / Sponsor and CMO / CDMO Relationships
15.7. Business Acquisition and Consolidation Activity

16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Batavia Biosciences
16.2.1 Company Snapshot
16.2.2 Interview Transcript: Menzo Havenga, CEO and Claire Otjes, Marketing Manager
16.3. Goodwin Biotechnology
16.3.1. Company Snapshot
16.3.2 Interview Transcript: David C Cunningham, Director Corporate Development
16.4. Statens Serum Institut
16.4.1. Company Snapshot
16.4.2 Interview Transcript: Ingrid Cromann, Director - Vaccine Development
16.5. Novasep Synthesis
16.5.1. Company Snapshot
16.5.2 Interview Transcript: Kevin Daley, Director Pharmaceuticals
16.6. ProBioGen
16.6.1. Company Snapshot
16.6.2 Interview Transcript: Oliver Schub, Senior Business Development Manager
16.7. Wacker Biotech
16.7.1 Company Snapshot
16.7.2 Interview Transcript: Sebastian Schuck, Head of Business Development

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1  Differences Between Vaccines and Small Molecule Drugs
Figure 3.2  Classification of Vaccines
Figure 3.3  Vaccine Manufacturing Process
Figure 3.4  Key Steps in Vaccine Transportation 
Figure 3.5  Types of Third-Party Service Providers in the Pharmaceutical Industry
Figure 3.6  Commonly Outsourced Vaccine Development Operations
Figure 3.7  Key Considerations for Selecting a CMO Partner
Figure 3.8 Risks and Challenges Associated with Contract Manufacturing
Figure 4.1  Vaccine CMOs: Distribution by Year of Establishment
Figure 4.2  Vaccine CMOs: Distribution by Size of Employee Base 
Figure 4.3  Vaccine CMOs: Distribution by Location of Headquarters (Region-wise)
Figure 4.4  Vaccine CMOs: Distribution by Location of Headquarters (Country-wise)
Figure 4.5  Vaccine CMOs: Distribution by Location of Manufacturing Facility (Region-wise)
Figure 4.6  Vaccine CMOs: Distribution by Location of Manufacturing Facility (Country-wise)
Figure 4.7  Vaccine CMOs: Distribution by Type of Services Offered
Figure 4.8  Vaccine CMOs: Distribution by Scale of Operation
Figure 4.9  Vaccine CMOs: Distribution by Expression System Used
Figure 4.10  Vaccine CMOs: Distribution by Type of Vaccines Manufactured
Figure 5.1.  Competitiveness Analysis of Vaccine Contract Manufacturers in North America
Figure 5.2.  Competitiveness Analysis of North American Service Providers Offering Contract Manufacturing of Vaccines based on Mammalian Expression 
Figure 5.3. Competitiveness Analysis of North American Service Providers Offering Contract Manufacturing of Vaccines based on Microbial Expression System
Figure 5.4.  Competitiveness Analysis of North American Service Providers Offering Contract Manufacturing of Vaccines based on Other Expression System
Figure 5.5.  Competitiveness Analysis of Vaccine Contract Manufacturers in Europe
Figure 5.6.  Competitiveness Analysis of European Service Providers Offering Contract Manufacturing of Vaccines based on Mammalian Expression System
Figure 5.7.  Competitiveness Analysis of European Service Providers Offering Contract Manufacturing of Vaccines based on Microbial Expression System
Figure 5.8.  Competitiveness Analysis of European Service Providers Offering Contract Manufacturing of Vaccines based on Other Expression System
Figure 5.9. Competitiveness Analysis of Vaccine Contract Manufacturers in Asia-Pacific 
Figure 5.10.  Competitiveness Analysis of Asia Pacific Service Providers Offering Contract Manufacturing of Vaccines based on Mammalian Expression System
Figure 5.11.  Competitiveness Analysis of Asia Pacific Service Providers Offering Contract Manufacturing of Vaccines based on Microbial Expression System
Figure 5.12.  Competitiveness Analysis of Asia Pacific Service Providers Offering Contract Manufacturing of Vaccines based on Other Expression System
Figure 6.1  AMRI: Annual Revenues, 2012- Q1 2017 (USD Million)
Figure 6.2  AMRI: Overview of Service Portfolio
Figure 6.3  Catalent: Revenues, 2013 – Q1 2019 (USD Million)
Figure 6.4  Catalent: Revenues by Business Divisions, 2018 (USD Million)
Figure 6.5  Catalent: Vaccine Manufacturing Services Portfolio 
Figure 6.6  Charles River Laboratories: Annual Revenues, 2011–2018 (USD Billion)
Figure 6.7  Charles River Laboratories: Distribution of Revenues by Business Segments, 2018 (USD Billion)
Figure 6.8  Charles River Laboratories: Products and Services
Figure 6.9  Meridian Life Science: Annual Revenues, 2013- H1 2019 (USD Million)
Figure 6.10 Merck: Annual Revenues, 2012 –2018 (EUR Billion)
Figure 6.11 Merck: Distribution of Revenues by Business Segments, 2018 (EUR Billion)
Figure 6.12  SAFC: Contract Manufacturing Support Services
Figure 6.13  SAFC Carlsbad Facility: Vaccine Manufacturing Services
Figure 7.1  Eurogentec: Manufacturing Technologies and Capabilities
Figure 7.2  IDT Biologika: Vaccine-related Service Portfolio
Figure 7.1 Lonza: Annual Revenues, 2012-2018 (CHF Million)
Figure 7.2  Lonza: Vaccine Manufacturing Services Portfolio 
Figure 8.1  Hong Kong Institute of Biotechnology: Service Portfolio
Figure 8.2  WuXi Biologics: Annual Revenues, 2014-2018 (RMB Million)
Figure 8.3  WuXi Biologics: Vaccine Development Services
Figure 8.4  WuXi Biologics: Vaccine Testing Services
Figure 9.1 Partnerships and Collaborations: Cumulative Trend by Year, 2013-2019
Figure 9.2  Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3  Partnerships and Collaborations: Trend by Type of Partnership and Year (2013-2018)
Figure 9.4  Partnerships and Collaborations: Distribution by Type of Vaccines
Figure 9.5  Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership  
Figure 9.6  Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
Figure 9.7  Partnerships and Collaborations: Most Active Players
Figure 9.8  Partnerships and Collaborations: Regional Distribution
Figure 9.9  Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 10.1  Facility Expansions: Distribution by Year, 2013-2019
Figure 10.2  Facility Expansions: Distribution by Type of Expansion
Figure 10.3  Facility Expansions: Distribution by Scale of Operation and Type of Expansion
Figure 10.4 Facility Expansions: Distribution by Geography and Year, 2013-2019
Figure 10.5  Facility Expansions: Distribution by Company Headquarters and Company Size
Figure 10.6  Facility Expansions: Distribution by Location of Facility and Type of Expansion
Figure 10.7  Facility Expansions: Distribution by Type of Services Offered
Figure 10.8  Facility Expansions: Distribution by Type of Services and Type of Expansion
Figure 10.9  Facility Expansions: Most Active Players
Figure 11.1  Vaccine Contract Manufacturing Market: Global Capacity: Distribution by Range of Installed Capacity
Figure 11.2  Capacity Analysis: Global Vaccine Contract Manufacturing Capacity by Size of CMOs
Figure 11.3  Capacity Analysis: Global Vaccine Contract Manufacturing Capacity based on Expression System
Figure 11.4  Capacity Analysis: Global Vaccine Contract Manufacturing Capacity based on Scale of Manufacturing
Figure 11.5  Capacity Analysis: Regional Distribution of Vaccine CMOs
Figure 11.6  Capacity Analysis: Vaccine Contract Manufacturing Capacity of the US
Figure 11.7  Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of Canada
Figure 11.8  Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of the UK
Figure 11.9  Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of Germany
Figure 11.10  Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of France
Figure 11.11 Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of Italy
Figure 11.12  Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of Spain
Figure 11.13  Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of rest of Europe
Figure 11.14  Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of South Korea
Figure 11.15  Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of India
Figure 11.16  Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of China
Figure 11.17  Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of Japan
Figure 11.18  Capacity Analysis: Regional Vaccine Contract Manufacturing Capacity of Rest of Asia and Middle East
Figure 12.1  Global Clinical Demand for Vaccines: Cumulative Distribution of Trials by Registration Year 
Figure 12.2  Global Clinical Demand for Vaccines: Distribution of Trials by Type of Vaccines
Figure 12.3  Global Clinical Demand for Vaccines:  Distribution of Trials by Phase
Figure 12.4  Global Clinical Demand for Vaccines:  Distribution of Trials by Status
Figure 12.5  Global Clinical Demand for Vaccines: Geographical Distribution of Trials (Country-Wise)
Figure 12.6  Global Clinical Demand for Vaccines: Geographical Distribution of Trials by Status and Phase
Figure 12.7  Global Clinical Demand for Vaccines:  Distribution of Trials by Type of Sponsors / Collaborators
Figure 12.8  Global Clinical Demand for Vaccines:  Most Active Industry Players in Terms of Number of Trials Conducted
Figure 12.9  Global Clinical Demand for Vaccines:  Most Active Non-Industry Players in Terms of Number of Trials Conducted
Figure 12.10  Global Clinical Demand for Vaccines:  Geographical Distribution of Enrolled Patient Population (Country-Wise)
Figure 12.11  Global Clinical Demand for Vaccines: Geographical Distribution of Enrolled Patient Population by Type of Vaccine
Figure 12.12  Global Clinical Demand for Vaccines: Annual Demand for Vaccines (in Liters) 
Figure 13.1  Overall Vaccine Contract Manufacturing Market, 2019-2030 (USD Million)
Figure 13.2  Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Type of Services Offered (USD Billion)
Figure 13.3  Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Expression System Used (USD Million)
Figure 13.4  Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 13.5  Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Size of Employee Base of Contract Manufacturers (USD Million)
Figure 13.6  Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Geography (USD Million)
Figure 13.7  Vaccine Contract Manufacturing Market in North America, 2019-2030 (USD Million)
Figure 13.8  Vaccine Contract Manufacturing Market in the US, 2019-2030 (USD Million)
Figure 13.9  Vaccine Contract Manufacturing Market in Rest of North America, 2019-2030 (USD Million)
Figure 13.10 Vaccine Contract Manufacturing Market in North America for Mammalian Cell-based Operations, 2019-2030 (USD Million)
Figure 13.11  Vaccine Contract Manufacturing Market in North America for Microbial Cell-based Operations, 2019-2030 (USD Million)
Figure 13.12  Vaccine Contract Manufacturing Market in North America for Other Expression System-based Operations, 2019-2030 (USD Million)
Figure 13.13  Vaccine Contract Manufacturing Market in North America for Preclinical / Clinical Scale Operations, 2019-2030 (USD Million)
Figure 13.14  Vaccine Contract Manufacturing Market in North America for Commercial Operations, 2019-2030 (USD Million)
Figure 13.15  Vaccine Contract Manufacturing Market in North America for Small-sized Companies, 2019-2030 (USD Million)
Figure 13.16  Vaccine Contract Manufacturing Market in North America for Mid-sized Companies, 2019-2030 (USD Million)
Figure 13.17  Vaccine Contract Manufacturing Market in North America for Large / Very Large Companies, 2019-2030 (USD Million)
Figure 13.18  Vaccine Contract Manufacturing Market in Europe, 2019-2030 (USD Million)
Figure 13.19  Vaccine Contract Manufacturing Market in Italy, 2019-2030 (USD Million)
Figure 13.20  Vaccine Contract Manufacturing Market in Germany, 2019-2030 (USD Million)
Figure 13.21 Vaccine Contract Manufacturing Market in France, 2019-2030 (USD Million)
Figure 13.22  Vaccine Contract Manufacturing Market in Spain, 2019-2030 (USD Million)
Figure 13.23  Vaccine Contract Manufacturing Market in the UK, 2019-2030 (USD Million)
Figure 13.24  Vaccine Contract Manufacturing Market in Rest of Europe, 2019-2030 (USD Million)
Figure 13.25  Vaccine Contract Manufacturing Market in Europe for Mammalian Cell-based Operations, 2019-2030 (USD Million)
Figure 13.26  Vaccine Contract Manufacturing Market in Europe for Microbial Cell-based Operations, 2019-2030 (USD Million)
Figure 13.27  Vaccine Contract Manufacturing Market in Europe for Other Expression System-based Operations, 2019-2030 (USD Million)
Figure 13.28  Vaccine Contract Manufacturing Market in Europe for Preclinical / Clinical Operations, 2019-2030 (USD Million)
Figure 13.29  Vaccine Contract Manufacturing Market in Europe for Commercial Operations, 2019-2030 (USD Million)
Figure 13.30  Vaccine Contract Manufacturing Market in Europe for Small-sized Companies, 2019-2030 (USD Million)
Figure 13.31 Vaccine Contract Manufacturing Market in Europe for Mid-sized Companies, 2019-2030 (USD Million)
Figure 13.32  Vaccine Contract Manufacturing Market in Europe for Large / Very Large Companies, 2019-2030 (USD Million)
Figure 13.33  Vaccine Contract Manufacturing Market in Asia and Rest of the World, 2019-2030 (USD Million)
Figure 13.34  Vaccine Contract Manufacturing Market in China, 2019-2030 (USD Million)
Figure 13.35  Vaccine Contract Manufacturing Market in India, 2019-2030 (USD Million)
Figure 13.36  Vaccine Contract Manufacturing Market in South Korea, 2019-2030 (USD Million)
Figure 13.37  Vaccine Contract Manufacturing Market in Japan, 2019-2030 (USD Million)
Figure 13.38  Vaccine Contract Manufacturing Market in Australia, 2019-2030 (USD Million)
Figure 13.39  Vaccine Contract Manufacturing Market in Rest of Asia and Other Regions, 2019-2030 (USD Million)
Figure 13.40  Vaccine Contract Manufacturing Market in Asia and Rest of the World for Mammalian Cell-based Operations, 2019-2030 (USD Million)
Figure 13.41 Vaccine Contract Manufacturing Market in Asia and Rest of the World for Microbial Cell-based Operations, 2019-2030 (USD Million)
Figure 13.42  Vaccine Contract Manufacturing Market in Asia and Rest of the World for Other Expression System-based Operations, 2019-2030 (USD Million)
Figure 13.43  Vaccine Contract Manufacturing Market in Asia and Rest of the World for Preclinical / Clinical Operations, 2019-2030 (USD Million)
Figure 13.44  Vaccine Contract Manufacturing Market in Asia and Rest of the World for Commercial Operations, 2019-2030 (USD Million)
Figure 13.45  Vaccine Contract Manufacturing Market in Asia and Rest of the World for Small-sized Companies, 2019-2030 (USD Million)
Figure 13.46  Vaccine Contract Manufacturing Market in Asia and Rest of the World for Mid-sized Companies, 2019-2030 (USD Million)
Figure 13.47  Vaccine Contract Manufacturing Market in Asia and Rest of the World for Large / Very Large Companies, 2019-2030 (USD Million)
Figure 14.1  Vaccine Contract Manufacturing: SWOT Analysis
Figure 14.2 Comparison of SWOT Factors: Harvey Ball Analysis

List of Tables

Table 3.1 Classification of Vaccines based on Method of Development 
Table 3.2  Live Attenuated Vaccines: Commonly Reported Adverse Events
Table 3.3  Inactivated Vaccines: Commonly Reported Adverse Events
Table 3.4  Subunit Vaccines: Commonly Reported Adverse Events
Table 3.5  Toxoid Vaccines: Commonly Reported Adverse Events
Table 3.6  Vaccine Excipients and their Functions
Table 4.1  Vaccine Contract Manufacturers: List of Service Providers
Table 4.2  Vaccine CMOs: Information on Type of Services Offered
Table 4.3  Vaccine CMOs: Information on Scale of Operation
Table 4.4  Vaccine CMOs: Information on Expression System Used
Table 4.5  Vaccine CMOs: Information on Type of Vaccines Manufactured
Table 6.1 Vaccine CMOs: List of Profiled Companies (North America)
Table 6.2  AMRI (OsoBio): Company Overview
Table 6.3  AMRI (OsoBio): Recent Partnerships
Table 6.4  Catalent Biologics: Company Overview
Table 6.5  Catalent: Biologics Manufacturing and Laboratory Facilities
Table 6.6  Catalent: Recent Partnerships
Table 6.7  Charles River Laboratories: Recent Partnerships
Table 6.8  Charles River Laboratories: Future Outlook
Table 6.9  Meridian Life Science: Recent Partnerships
Table 6.10 BioReliance: Company Overview
Table 6.11  Merck: Recent Partnerships
Table 7.1 Vaccine CMOs: List of Profiled Companies (Europe)
Table 7.2  Cobra Biologics: Recent Partnerships
Table 7.3  IDT Biologika: Recent Partnerships
Table 7.4  Lonza: Company Overview
Table 7.5  Lonza: Recent Partnerships
Table 8.1  Vaccine CMOs: List of Profiled Companies (Emerging Regions)
Table 8.2  Hong Kong Institute of Biotechnology: Vaccine Contract Manufacturing Services
Table 8.3  WuXi Biologics: Biologics Development and Manufacturing Services
Table 8.4  WuXi Biologics: Recent Partnerships
Table 8.5  Bharat Biotech: Recent Partnerships
Table 8.6  Biological E: Recent Partnerships
Table 9.1  Vaccine Contract Manufacturing Market: Partnerships and Collaborations, 2013-2019
Table 10.1  Vaccine Contract Manufacturing Market: List of Recent Expansions, 2013-2019
Table 10.2  Expansions: Information on Types of Services
Table 14.1  Capacity Analysis: CMO Size Adjustments based on Capacity
Table 14.2  Capacity Analysis: CMO Size Adjustments based on Size of Employee Base
Table 14.3  Capacity Analysis: Key Assumptions and Inputs
Table 14.4  Capacity Analysis: Global Contract Vaccine Manufacturing Capacity  
Table 14.5  Capacity Analysis: Regional Contract Vaccine Manufacturing Capacity
Table 17.1  Vaccine CMOs: Distribution by Year of Establishment
Table 17.2  Vaccine CMOs: Distribution by Size of Employee Base
Table 17.3  Vaccine CMOs: Distribution by Location of Headquarters (Region-wise)
Table 17.4  Vaccine CMOs: Distribution by Location of Headquarters (Country-wise)
Table 17.5  Vaccine CMOs: Distribution by Location of Manufacturing Facility (Region-wise)
Table 17.6  Vaccine CMOs: Distribution by Location of Manufacturing Facility (Country-wise)
Table 17.7  Vaccine CMOs: Distribution by Type of Services Offered
Table 17.8  Vaccine CMOs: Distribution by Scale of Operation
Table 17.9  Vaccine CMOs: Distribution by Expression System Used
Table 17.10  Vaccine CMOs: Distribution by Type of Vaccines Manufactured
Table 17.11  AMRI: Annual Revenues (USD Million)
Table 17.12  Catalent: Annual Revenues (USD Million)
Table 17.13  Catalent: Annual Revenues by Business Divisions (USD Million)
Table 17.14  Charles River Laboratories: Annual Revenues (USD Billion)
Table 17.15  Charles River Laboratories: Distribution of Revenues by Business Segments (USD Billion)
Table 17.16  Meridian Life Science: Annual Revenues (USD Million)
Table 17.17  Merck: Annual Revenues (EUR Billion)
Table 17.18  Lonza: Annual Revenues (CHF Billion)
Table 17.19  Wuxi Biologics: Annual Revenues (RMB Million)
Table 17.20  Wuxi Biologics: Annual Revenues by Regions of Operation (RMB million)
Table 17.21.  Partnerships and Collaborations: Distribution by Year, 2013-2019
Table 17.22.  Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.23.  Partnerships and Collaborations: Distribution by Type of Partnership and Year
Table 17.24.  Partnerships and Collaborations: Distribution by Type of Vaccines
Table 17.25.  Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership 
 Table 17.26.  Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership 
Table 17.27.  Partnerships and Collaborations: Most Active Players
Table 17.28.  Partnerships and Collaborations: Distribution by Geographical Location
Table 17.29.  Facility Expansions: Distribution by Year, 2013-2019
Table 17.30.  Facility Expansions: Distribution by Type of Expansion
Table 17.31.  Facility Expansions: Distribution by Scale of Operation and Type of Expansion
Table 17.32.  Facility Expansions: Distribution by Distribution by Company Headquarters and Company Size
Table 17.33.  Facility Expansions: Distribution by Location of Facility and Type of Expansion 
Table 17.34.  Facility Expansions: Distribution by Types of Services Offered
Table 17.35.  Facility Expansions: Distribution by Types of Services and Type of Expansion
Table 17.36.  Facility Expansions: Most Active Players
Table 17.37  Capacity Analysis: Global Contract Biomanufacturing Capacity by Size of CMOs
Table 17.38  Capacity Analysis: Global Vaccine Contract Manufacturing Capacity based on Expression System 
Table 17.39  Capacity Analysis: Global Vaccine Contract Manufacturing Capacity based on Scale of Manufacturing
Table 17.40  Overall Vaccine Contract Manufacturing Market, 2019-2030 (USD Million)
Table 17.41 Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Type of Services Offered (USD Billion)
Table 17.42 Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Expression System Used (USD Billion)
Table 17.43 Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation (USD Billion)
Table 17.44  Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Size of Employee Base of Contract Manufacturers (USD Billion)
Table 17.45 Vaccine Contract Manufacturing Market, 2019-2030: Distribution by Geography (USD Billion)
Table 17.46  Vaccine Contract Manufacturing Market in North America, 2019-2030 (USD Million)
Table 17.47  Vaccine Contract Manufacturing Market in the US, 2019-2030 (USD Million)
Table 17.48  Vaccine Contract Manufacturing Market in Rest of North America, 2019-2030 (USD Million)
Table 17.49  Vaccine Contract Manufacturing Market in North America for Mammalian Cell-based Operations, 2019-2030 (USD Million)
Table 17.50  Vaccine Contract Manufacturing Market in North America for Microbial Cell-based Operations, 2019-2030 (USD Million)
Table 17.51  Vaccine Contract Manufacturing Market in North America for Other Expression System-based Operations, 2019-2030 (USD Million)
Table 17.52  Vaccine Contract Manufacturing Market in North America for Preclinical / Clinical Scale Operations, 2019-2030 (USD Million)
Table 17.53  Vaccine Contract Manufacturing Market in North America for Commercial Operations, 2019-2030 (USD Million)
Table 17.54  Vaccine Contract Manufacturing Market in North America for Small-sized Companies, 2019-2030 (USD Million)
Table 17.55  Vaccine Contract Manufacturing Market in North America for Mid-sized Companies, 2019-2030 (USD Million)
Table 17.56  Vaccine Contract Manufacturing Market in North America for Large / Very Large Companies, 2019-2030 (USD Million)
Table 17.57 Vaccine Contract Manufacturing Market in Europe, 2019-2030 (USD Million)
Table 17.58  Vaccine Contract Manufacturing Market in Italy, 2019-2030 (USD Million)
Table 17.59  Vaccine Contract Manufacturing Market in Germany, 2019-2030 (USD Million)
Table 17.60  Vaccine Contract Manufacturing Market in France, 2019-2030 (USD Million)
Table 17.61  Vaccine Contract Manufacturing Market in Spain, 2019-2030 (USD Million)
Table 17.62  Vaccine Contract Manufacturing Market in the UK, 2019-2030 (USD Million)
Table 17.63  Vaccine Contract Manufacturing Market in Rest of Europe, 2019-2030 (USD Million)
Table 17.64  Vaccine Contract Manufacturing Market in Europe for Mammalian Cell-based Operations, 2019-2030 (USD Million)
Table 17.65  Vaccine Contract Manufacturing Market in Europe for Microbial Cell-based Operations, 2019-2030 (USD Million)
Table 17.66  Vaccine Contract Manufacturing Market in Europe for Other Expression System-based Operations, 2019-2030 (USD Million)
Table 17.67  Vaccine Contract Manufacturing Market in Europe for Preclinical / Clinical Operations, 2019-2030 (USD Million)
Table 17.68  Vaccine Contract Manufacturing Market in Europe for Commercial Operations, 2019-2030 (USD Million)
Table 17.69  Vaccine Contract Manufacturing Market in Europe for Small-sized Companies, 2019-2030 (USD Million)
Table 17.70  Vaccine Contract Manufacturing Market in Europe for Mid-sized Companies, 2019-2030 (USD Million)
Table 17.71  Vaccine Contract Manufacturing Market in Europe for Large / Very Large Companies, 2019-2030 (USD Million)
Table 17.72  Vaccine Contract Manufacturing Market in Asia and Rest of the World, 2019-2030 (USD Million)
Table 17.73  Vaccine Contract Manufacturing Market in China, 2019-2030 (USD Million)
Table 17.74  Vaccine Contract Manufacturing Market in India, 2019-2030 (USD Million)
Table 17.75  Vaccine Contract Manufacturing Market in South Korea, 2019-2030 (USD Million)
Table 17.76  Vaccine Contract Manufacturing Market in Japan, 2019-2030 (USD Million)
Table 17.77  Vaccine Contract Manufacturing Market in Australia, 2019-2030 (USD Million)
Table 17.78  Vaccine Contract Manufacturing Market in Rest of Asia and Other Regions, 2019-2030 (USD Million)
Table 17.79  Vaccine Contract Manufacturing Market in Asia and Rest of the World for Mammalian Cell-based Operations, 2019-2030 (USD Million)
Table 17.80  Vaccine Contract Manufacturing Market in Asia and Rest of the World for Microbial Cell-based Operations, 2019-2030 (USD Million)
Table 17.81  Vaccine Contract Manufacturing Market in Asia and Rest of the World for Other Expression System-based Operations, 2019-2030 (USD Million)
Table 17.82  Vaccine Contract Manufacturing Market in Asia and Rest of the World for Preclinical / Clinical Operations, 2019-2030 (USD Million)
Table 17.83  Vaccine Contract Manufacturing Market in Asia and Rest of the World for Commercial Operations, 2019-2030 (USD Million)
Table 17.84  Vaccine Contract Manufacturing Market in Asia and Rest of the World for Small-sized Companies, 2019-2030 (USD Million)
Table 17.85  Vaccine Contract Manufacturing Market in Asia and Rest of the World for Mid-sized Companies, 2019-2030 (USD Million)
Table 17.86  Vaccine Contract Manufacturing Market in Asia and Rest of the World for Large / Very Large Companies, 2019-2030 (USD Million)

List of Companies

  1. 3P Biopharmaceuticals
  2. Acambis
  3. Accugenix
  4. Actavis
  5. Advanced BioScience Laboratories
  6. Advaxis
  7. Aeras
  8. AGC Biologics
  9. AJ Biologics
  10. Albany Molecular Research
  11. Alexion Pharmaceuticals
  12. Algonomics
  13. Altaris Capital Partners
  14. AmbioPharm
  15. AnaSpec
  16. Aptuit
  17. Association for Assessment and Accreditation of Laboratory Animal Care
  18. Avid Bioservices
  19. Bachem
  20. Batavia Biosciences
  21. Battelle
  22. Bavarian Nordic
  23. Baxter BioPharma Solutions
  24. Baylor Institute for Immunology Research
  25. BD Biosciences
  26. Benchmark Vaccines
  27. Bharat Biotech
  28. Bill & Melinda Gates Foundation
  29. Bilthoven Biologicals
  30. Biocell
  31. Biocon
  32. BioConnections
  33. BioConvergence
  34. Biofabri
  35. Bioline
  36. Biological E
  37. BioMARC
  38. Biomay
  39. Biomedical Advanced Research and Development Authority
  40. BioMotiv
  41. BiondVax Pharmaceuticals
  42. BioReliance
  43. BioTechnique
  44. Biotechnology and Biological Sciences Research Council
  45. Biovest International
  46. Birgi Mefar Group
  47. Boehringer Ingelheim
  48. Boston Children’s Hospital
  49. Bristol-Myers Squibb
  50. Bryllan
  51. CALIXAR
  52. Canadian Animal Health Institute
  53. Canadian Council on Animal Care
  54. Catalent
  55. Celsis International
  56. Cetus
  57. CEVEC Pharmaceuticals
  58. Charles River Biopharmaceutical Services
  59. Charles River Laboratories
  60. Chimera Biotec
  61. China Agricultural University
  62. China National Biotec Group
  63. Chinese Center for Disease Control and Prevention
  64. Chinese University of Hong Kong
  65. Chiron Behring Vaccines (acquired by Bharat Biotech)
  66. Cobra Biologics
  67. Cook Pharmica
  68. Crucell Sweden
  69. Cytovance Biologics
  70. Daiichi Sankyo
  71. Deltamune
  72. Dr. Reddy's Laboratories
  73. Dyadic International
  74. EGYVAC
  75. Emergent BioSolutions
  76. Engineering and Physical Sciences Research Council
  77. EuBiologics
  78. Eurogentec
  79. European Medicines Agency
  80. ExpreS2ion Biotech Holding
  81. Exxell BIO
  82. Federation of Indian Chambers of Commerce and Industry
  83. Florida Biologix
  84. French National Agency for Research on AIDS and Viral Hepatitis
  85. Friedrich-Loeffler-Institut
  86. FUJIFILM Diosynth Biotechnologies
  87. Gallant Custom Laboratories
  88. Gamma Vaccines
  89. GAVI
  90. Genentech
  91. GENEWIZ
  92. Genzyme Polyclonals
  93. GlaxoSmithKline
  94. GNH India Pharmaceuticals
  95. Goodwin Biotechnology
  96. Grand River Aseptic Manufacturing
  97. Greenpak Biotech
  98. Grifols
  99. Guangxi Veterinary Research Institute
  100. Guangzhou Air force Hospital
  101. Haffkine Institute
  102. HALIX
  103. Harbin Veterinary Research Institute
  104. Hennepin Healthcare Research Institute
  105. HLL Biotech
  106. Hong Kong Institute of Biotechnology
  107. IDT Biologika
  108. ImevaX
  109. Immune Design
  110. Immune Targeting Systems (acquired by Vaxin)
  111. ImmunoSite Technologies
  112. ImVisioN Therapeutics
  113. Index Ventures
  114. Indian Council of Medical Research
  115. Indian Immunologicals
  116. Infectious Disease Research Institute
  117. Innovate UK
  118. Integrity Bio
  119. International Medica Foundation
  120. International Society for Pharmaceutical Engineering
  121. Interros
  122. Intervacc
  123. Inviragen (acquired by Takeda)
  124. Irvine Pharmaceutical Services (acquired by Nitto Avecia Pharma Services)
  125. Israel Institute for Biological Research
  126. Jubilant HollisterStier
  127. KABS Pharmaceutical Services
  128. Kalon Biotherapeutics
  129. Kaneka
  130. KBI Biopharma
  131. LigoCyte Pharmaceuticals
  132. Lonza
  133. Luina Bio
  134. Magellan BioScience Group
  135. MassBiologics
  136. Medicago
  137. Medicines and Healthcare products Regulatory Agency
  138. Merck
  139. Meridian Life Science
  140. Mitsubishi Gas Chemical
  141. Mitsubishi Tanabe Pharma
  142. Moderna Therapeutics
  143. Mymetics
  144. Najít Technologies
  145. National Avian Influenza Reference Laboratory
  146. National Heart, Lung, and Blood Institute
  147. National Institutes of Allergy and Infectious Diseases
  148. NewLink Genetics
  149. Norwegian Institute of Public Health
  150. Nouscom
  151. Novartis
  152. Novasep
  153. Novavax
  154. NPO Petrovax Pharm
  155. OctoPlus
  156. Okairos
  157. Oncotest
  158. Organization for Economic Cooperation and Development
  159. OSO BioPharmaceuticals Manufacturing
  160. Pacific GMP
  161. Panacea Biotec
  162. Paragon Bioservices
  163. PATH
  164. PaxVax
  165. Pfenex
  166. Pfizer
  167. Pfizer CentreOne
  168. PharmaPak
  169. PharmaSynth
  170. Premas Biotech
  171. Prime European Therapeuticals
  172. ProBioGen
  173. Protagen
  174. PX’Therapeutics
  175. QuiaPEG Pharmaceuticals
  176. RAFAGEN
  177. Recipharm
  178. Richter-Helm
  179. RIEMSER Pharma
  180. SAFC
  181. Sanofi Active Ingredient Solutions
  182. Sanofi Pasteur
  183. Sartorius Stedim Biotech
  184. Serum Institute of India
  185. Shandong Zhaoxin Bio-tech
  186. Shanghai Laboratory Animal Center
  187. ShangPharma Innovation
  188. SialoCarb
  189. Sichuan Agricultural University
  190. Sigma-Aldrich
  191. SK Chemicals
  192. Soligenix
  193. South China Agricultural University
  194. State Secretariat for Education, Research and Innovation
  195. Statens Serum Institut
  196. Stellar Biotechnologies
  197. Sumagen
  198. SynCo Bio Partners
  199. Synthelis
  200. Takeda Pharmaceuticals
  201. Temasek Life Sciences Ventures
  202. The Hong Kong Jockey Club Charities Trust
  203. Thermo Fisher Scientific
  204. Thomas Jefferson University
  205. Tianjin CanSino Biotechnology
  206. Transgene
  207. Unitech Pharma Group
  208. United States Army Medical Research Institute of Infectious Diseases
  209. Univercells
  210. University of Copenhagen
  211. University of Maryland
  212. University of Oxford
  213. University of Pennsylvania
  214. Upperton Pharma Solutions
  215. Vaccibody
  216. VACSERA
  217. Valerius Biopharma
  218. Valneva
  219. Vaxin
  220. Vetter Pharma
  221. VGXI
  222. Vibalogics
  223. Vivalis
  224. Vybion
  225. Waisman Biomanufacturing
  226. Walter Reed Army Institute of Research
  227. Wellcome Trust
  228. WIL Research
  229. World Trade Organization
  230. WuXi AppTec
  231. Wuxi Fortune Pharmaceutical
  232. Zoetis

Segmentation

The financial opportunity of over USD 4 billion (by 2030) within the vaccine contract manufacturing market has been analyzed across the following segments:

  • Scale of Operation
    • Preclinical 
    • Clinical
    • Commercial
  • Type of Expression System
    • Mammalian
    • Microbial
    • Others
  • Outsourced Business Operations
    • API Manufacturing
    • Fill / Finish
    • Others
  • Key geographical regions 
    • North America (US, Rest of North America)
    • Europe ((UK, France, Germany, Italy, Spain and rest of the Europe)
    • Asia-Pacific (India, China and Rest of Asia)
    • Rest of the World

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com